Supplementary Table 1.

Clinical information in nine cases of CD56⁺ pDCs proliferation associated with myeloid tumor

Cases	Age (years)/gender	Associated myeloid tumor	L	S	H	Skin lesions	Site of pDCs accumulation	Treatment	Survival (months)
1[2]	24/male	CMML	+	+	+	+	LN, SK	--	8 (DOD)
2[2]	50/male	AML-M4	+	+	+	+	LN, SK, BM	--	11 (AWD)
3[2]	63/female	U-CMP	+	+	–	–	LN, BM	--	15 (DOD)
4[2]	80/male	U-MDS/MP	+	+	+	+	LN, BM	--	43 (DOD)
5[2]	62/female	AML-M5	+	–	–	–	LN, BM	--	15 (DOD)
6[2]	52/male	CMML	+	+	–	–	LN, BM	--	13 (AWD)
7[3]	56/male	AML transferred from CD56+ TdT+ blastic tumor of skin	+	–	–	+	LN, SK, BM	Hyper-CVAD POMP maintenance troxacitabine/cytarabine	15 (DOD)
8[3]	73/male	AML transferred from CD56+ TdT+ blastic tumor of skin	+	–	–	+	LN, SK, BM	Hyper-CVAD and methotrexate/cytarabine salvage treatment	22 (DOD)
Our patient	83/male	AML-M4 transferred from PMF coexisted with MGUS	+	–	–	–	BM	Supportive treatment	3 (DOD)

pDCs: Plasmacytoid dendritic cells; CMML: Chronic myelomonocytic leukemia; AML: Acute myeloid leukemia; U-CMP: Unclassifiable chronic myeloproliferative disorder; U-MDS/MP: Unclassifiable myeloproliferative/myelodysplastic disorder; PMF: Primary myelofibrosis; MGUS: Monoclonal gammopathy of undetermined significance; L: Lymphadenopathy; S: Splenomegaly; H: Hepatomegaly; LN: Lymph node; BM: Bone marrow; SK: Skin; Hyper-CVAD: Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; POMP: Mercaptopurine, methotrexate, vincristine, and prednisone; DOD: Dead of disease; AWD: Alive with disease; +: Yes; -: No; --: No clear information.